Kura Oncology, Inc. (KURA) has a negative trailing P/E of -2.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 12.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -35.96%, forward earnings yield 8.10%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.0 | 0.11 | 1.94 | 0.00 | - |
| 2017 | -10.0 | -2.95 | 4.45 | 0.00 | - |
| 2018 | -8.2 | -0.62 | 3.07 | 0.00 | - |
| 2019 | -9.1 | 0.75 | 2.64 | 0.00 | - |
| 2020 | -19.3 | -1.62 | 2.84 | 0.00 | - |
| 2021 | -7.1 | -0.43 | 1.83 | 0.00 | - |
| 2022 | -6.1 | -2.01 | 1.98 | 0.00 | - |
| 2023 | -6.9 | -2.80 | 2.65 | 0.00 | - |
| 2024 | -4.3 | 1.50 | 1.81 | 13.93 | - |
| 2025 | -3.3 | -0.06 | 5.23 | 13.50 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.47 | $0.00 | $-27.56M | - |
| 2017 | $-1.52 | $0.00 | $-35.43M | - |
| 2018 | $-1.72 | $0.00 | $-60.45M | - |
| 2019 | $-1.51 | $0.00 | $-63.14M | - |
| 2020 | $-1.68 | $0.00 | $-89.43M | - |
| 2021 | $-1.96 | $0.00 | $-129.91M | - |
| 2022 | $-2.03 | $0.00 | $-136.07M | - |
| 2023 | $-2.08 | $0.00 | $-152.63M | - |
| 2024 | $-2.02 | $53.88M | $-173.98M | -322.9% |
| 2025 | $-3.18 | $67.48M | $-278.67M | -412.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.52 | $-4.50 – $-1.49 | $111.4M | $59.05M – $267.64M | 9 |
| 2027 | $-2.59 | $-3.64 – $0.37 | $232.59M | $108.77M – $598.9M | 9 |
| 2028 | $-1.44 | $-3.62 – $3.47 | $362.76M | $362.71M – $362.81M | 9 |
| 2029 | $0.74 | $0.19 – $2.52 | $701.62M | $301.4M – $2B | 3 |
| 2030 | $3.93 | $1.02 – $13.39 | $1.23B | $528.89M – $3.51B | 3 |
